Recombinant Human T-cell surface glycoprotein CD3 delta chain (CD3D)

What is CD3D and what is its role in the T cell receptor complex?

CD3D (CD3 delta chain) is an invariant chain of the T cell receptor-CD3 complex essential for TCR assembly, transport, and cell surface expression. It forms a heterodimer with CD3ε (CD3D-CD3ε) that pairs with the CD3γ-CD3ε heterodimer and the ζζ/CD247 homodimer to create the complete TCR complex . Although CD3D shares high sequence homology with CD3γ (57% amino acid homology between human and mouse), these proteins have distinct and non-redundant functions in TCR assembly and signaling . Methodologically, researchers investigating CD3D structure-function relationships typically use techniques such as co-immunoprecipitation, FRET analysis, and site-directed mutagenesis to study its interactions within the TCR complex.

How does CD3D expression correlate with immune cell infiltration in tumors?

CD3D expression strongly correlates with tumor-infiltrating immune cells, particularly T cells. High CD3D expression is associated with increased infiltration of CD8+ T cells, CD4+ memory T cells, B cells, NK cells, M1 macrophages, and dendritic cells . Research shows that CD3D has the strongest correlation with CD8+ T cells and activated CD4+ memory T cells (Spearman Correlation Coefficient r>0.5) . Methodologically, researchers typically assess this correlation using computational methods such as CIBERSORT and ESTIMATE algorithms on transcriptomic data, followed by validation with immunohistochemistry or flow cytometry to quantify immune cell populations in tissue samples.

What experimental models are available for studying human CD3D?

Several experimental models are available for studying human CD3D:

• Cell line models: Jurkat T cell lines with stable CD3D knockdown using shRNA

• Humanized mouse models: Mice with entire CD3 complex (CD3E, CD3D, and CD3G) replaced with human counterparts

• In vitro T cell development models: Human T-cell progenitors with CD3D knockdown followed by mouse fetal thymus organ cultures

The humanized CD3 EDG mouse model is particularly valuable as it allows for the evaluation of human CD3-targeted therapeutics in vivo while maintaining immune competence . When selecting a model, researchers should consider whether they need to study the protein in isolation (cell lines) or within the context of a complete immune system (humanized mice).

How does CD3D deficiency differ from CD3G deficiency in terms of T cell development?

CD3D deficiency has more severe clinical consequences than CD3G deficiency, despite their structural similarities. In humans:

Notably, immature polyclonal T lymphocytes show high plasticity that allows for expression of significant TCR levels that may signal for survival in CD3γ deficiency but not in CD3δ deficiency . This explains the clinical disparities between these immunodeficiencies. Methodologically, researchers should assess both mature and developing T cells when studying these deficiencies, as the impacts differ significantly between developmental stages.

What mechanisms underlie CD3D's prognostic value in different cancer types?

CD3D has emerged as a significant prognostic biomarker in multiple cancer types, including colon adenocarcinoma (COAD) and breast carcinoma (BRCA). The mechanisms underlying its prognostic value include:

• Immune activation: High CD3D expression correlates with enrichment of immune-related pathways, particularly T cell receptor signaling, natural killer cell-mediated cytotoxicity, and chemokine signaling

• Correlation with immune checkpoints: CD3D expression strongly correlates with immune checkpoint molecules, suggesting its involvement in regulating T cell function in the tumor microenvironment

• Association with microsatellite status: CD3D expression decreases with increasing clinical stage and microsatellite status in COAD, potentially reflecting changes in immunogenicity

Methodologically, Gene Set Enrichment Analysis (GSEA) is commonly used to identify the pathways associated with CD3D expression. Multivariate Cox regression analysis can determine whether CD3D is an independent prognostic factor when accounting for other clinical variables . For researchers exploring CD3D as a prognostic biomarker, it is recommended to perform both univariate and multivariate analyses, and to validate findings across independent cohorts.

How can researchers effectively design knockdown experiments to study CD3D function?

When designing knockdown experiments to study CD3D function, researchers should consider:

• Cell type selection: Effects of CD3D knockdown differ between mature and immature T cells. In mature T cells, CD3D knockdown severely impairs TCR surface expression, whereas immature T cells show more plasticity

• Knockdown method: Stable shRNA knockdown in Jurkat T cells has been effective for studying CD3D function in mature T cells . For developing T cells, knockdown in T-cell progenitors followed by mouse fetal thymus organ cultures can be used

• Controls and comparisons: Include CD3G knockdown controls to distinguish between general CD3 complex deficiency effects and CD3D-specific effects

• Measurement parameters: Assess TCR assembly (co-immunoprecipitation), transport (ER retention markers), surface expression (flow cytometry), and functional outcomes (calcium flux, cytokine production)

A comprehensive experimental design should examine both structural (complex formation) and functional (signaling) aspects of CD3D to fully understand its role in T cell biology.

What are the current approaches for correcting CD3D mutations in CD3 delta SCID?

CD3 delta severe combined immunodeficiency (SCID) is a rare genetic disorder caused by mutations in the CD3D gene. Current approaches for correcting these mutations include:

• Base editing technology: Recent UCLA-led research has demonstrated that base editing, an ultraprecise form of genome editing, can correct single-letter mutations in the CD3D gene in blood stem cells . This technique allows for direct conversion of one DNA base to another without requiring double-strand breaks

• Methodological considerations for base editing approaches:

  • Target specificity assessment to minimize off-target effects

  • Optimization of delivery methods for hematopoietic stem cells

  • Evaluation of edited cells' ability to develop into functional T cells

  • Long-term engraftment studies in immunodeficient mouse models

Base editing represents a promising one-time treatment approach for CD3 delta SCID, potentially restoring normal T cell development from corrected blood stem cells . Researchers working on genetic correction of CD3D should carefully assess both editing efficiency and functional recovery of T cell development in their experimental designs.

How does CD3D interact with immune checkpoints, and what are the implications for cancer immunotherapy?

CD3D expression shows strong positive correlation with immune checkpoint molecules, suggesting complex interactions within the tumor microenvironment:

• Correlation patterns: Analysis of TCGA data reveals that CD3D expression positively correlates with multiple immune checkpoints in both COAD and BRCA . This suggests that tumors with high CD3D expression may have both active anti-tumor immunity and accompanying immunosuppressive mechanisms

• Mechanistic implications: The association between CD3D and immune checkpoints suggests that CD3D may play a role in regulating T cell functions in the tumor microenvironment, potentially through:

  • Direct physical interactions with checkpoint molecules

  • Shared regulatory pathways affecting both CD3D and checkpoint expression

  • Sequential upregulation where T cell activation (marked by CD3D) induces checkpoint expression as a feedback mechanism

• Therapeutic implications: The strong correlation between CD3D and immune checkpoints suggests potential synergy between CD3-targeted therapies and immune checkpoint inhibitors . Tumors with high CD3D expression may be more responsive to checkpoint inhibition due to the presence of activated T cells

Researchers investigating these interactions should employ co-immunoprecipitation, proximity ligation assays, and functional studies with checkpoint inhibitors in the presence of varying CD3D expression levels to elucidate the precise relationships.

What methodological approaches are most effective for studying CD3D in single-cell analyses of the tumor microenvironment?

Single-cell analysis offers unique insights into CD3D function within heterogeneous tumor microenvironments. Effective methodological approaches include:

• Single-cell RNA sequencing (scRNA-seq): This technique can reveal CD3D expression patterns in different T cell subsets within the tumor microenvironment. Evidence shows that CD3D is highly expressed in CD8+ T cells infiltrating tumors

• Analytical considerations for scRNA-seq data:

  • Dimensional reduction techniques (tSNE, UMAP) to visualize CD3D-expressing cell clusters

  • Trajectory analysis to track CD3D expression changes during T cell differentiation/exhaustion

  • Integration with TCR sequencing to link CD3D expression with TCR clonality

  • Cell-cell interaction analyses to identify communication between CD3D+ cells and other immune or tumor cells

• Spatial transcriptomics: Combining CD3D expression data with spatial information can reveal the relationship between CD3D+ T cells and tumor architecture, including invasive margins versus tumor core localization

• Validation approaches: Multiplex immunofluorescence to confirm co-expression of CD3D with other markers identified in scRNA-seq, particularly immune checkpoints and activation/exhaustion markers

Researchers should combine these approaches to comprehensively characterize CD3D+ cells' phenotypes, functions, and spatial distributions within the tumor microenvironment.